Medpace holdings general counsel Stephen Ewald buys shares worth $652

Published 28/02/2025, 22:42
Medpace holdings general counsel Stephen Ewald buys shares worth $652

Medpace Holdings (NASDAQ:MEDP), based in Cincinnati, is a company involved in commercial physical and biological research services. With a market capitalization of $9.9 billion, the company has demonstrated strong performance with 11.8% revenue growth over the last twelve months and maintains a healthy P/E ratio of 25. InvestingPro analysis reveals 8 additional key insights about MEDP’s performance and valuation, available in the comprehensive Pro Research Report, which provides deep-dive analysis of 1,400+ top US stocks. With a market capitalization of $9.9 billion, the company has demonstrated strong performance with 11.8% revenue growth over the last twelve months and maintains a healthy P/E ratio of 25. InvestingPro analysis reveals 8 additional key insights about MEDP’s performance and valuation, available in the comprehensive Pro Research Report, which provides deep-dive analysis of 1,400+ top US stocks.

Medpace Holdings, based in Cincinnati, is a company involved in commercial physical and biological research services.

In other recent news, Medpace Holdings, Inc. reported fourth-quarter earnings that exceeded analyst expectations. The company posted an adjusted earnings per share of $3.67, surpassing the consensus estimate of $2.94. Revenue for the quarter was $536.6 million, slightly above the projected $534.86 million and marking a 7.7% increase from the same quarter last year. However, Medpace’s 2025 revenue guidance of $2.11 billion to $2.21 billion fell short of the $2.238 billion analysts anticipated, causing concern among investors. This outlook suggests a growth range of 0.0% to 4.8% over the 2024 revenue of $2.109 billion.

CEO August Troendle noted a cautious approach to the 2025 forecast due to economic uncertainties. The company reported net new business awards of $529.7 million for the fourth quarter, a 13.8% decrease year-over-year, with a net book-to-bill ratio of 0.99x. Medpace’s backlog increased by 3.2% to $2.90 billion as of December 31, 2024. Additionally, the board approved a $600 million increase to its stock repurchase program, with 527,160 shares repurchased at an average price of $330.43 per share during the quarter.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.